STI 9167
Alternative Names: COVISHIELD - Sorrento Therapeutics; COVISHIELD antibody - Sorrento Therapeutics; STI-9167; STI-9199Latest Information Update: 28 Jun 2025
At a glance
- Originator Mount Sinai Health System
- Developer Sorrento Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in USA (Intranasal, Liquid)
- 28 Jun 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in USA (Intranasal, Liquid)
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (IV)